Syros Pharmaceuticals, Inc. (SYRS)
OTCMKTS · Delayed Price · Currency is USD
0.0008
0.00 (0.00%)
Feb 5, 2026, 4:00 PM EST

Syros Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
0.399.9414.8823.4915.091.98
Revenue Growth (YoY)
-95.61%-33.23%-36.65%55.62%661.50%-3.32%
Cost of Revenue
88.64108.15111.94---
Gross Profit
-88.25-98.22-97.0623.4915.091.98
Selling, General & Admin
23.2728.2829.323.0421.3321.48
Research & Development
---99.8776.0758.25
Operating Expenses
23.2728.2829.3122.9197.3979.72
Operating Income
-111.52-126.5-126.36-99.42-82.3-77.74
Interest Expense
-5.33-5.13-4.13-3.91-1.79-0.07
Interest & Investment Income
4.716.822.130.090.432.38
Other Non Operating Income (Expenses)
14.47-37.2833.7116.68-0.38-
EBT Excluding Unusual Items
-97.68-162.09-94.65-86.56-84.04-75.44
Merger & Restructuring Charges
-0.14-2.49----
Pretax Income
-97.82-164.57-94.65-86.56-84.04-75.44
Net Income
-97.82-164.57-94.65-86.56-84.04-75.44
Net Income to Common
-97.82-164.57-94.65-86.56-84.04-75.44
Shares Outstanding (Basic)
372813654
Shares Outstanding (Diluted)
372813654
Shares Change (YoY)
31.77%124.24%102.00%35.79%14.49%23.17%
EPS (Basic)
-2.66-5.81-7.49-13.84-18.25-18.76
EPS (Diluted)
-2.66-5.81-7.49-13.84-18.25-18.76
Free Cash Flow
-100.05-109.98-124.31-100.79-60.7-72.89
Free Cash Flow Per Share
-2.72-3.88-9.84-16.12-13.18-18.12
Gross Margin
---100.00%100.00%100.00%
Operating Margin
-28891.71%-1273.14%-849.21%-423.28%-545.27%-3922.35%
Profit Margin
-25340.67%-1656.34%-636.12%-368.52%-556.80%-3806.15%
Free Cash Flow Margin
-25920.72%-1106.87%-835.39%-429.09%-402.17%-3677.65%
EBITDA
-110.18-124.25-123.66-96.4-79.26-75.02
D&A For EBITDA
1.342.252.713.023.042.72
EBIT
-111.52-126.5-126.36-99.42-82.3-77.74
Updated Oct 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.